Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials

Abstract Proprotein convertase subtilisin/kexin9 monoclonal antibodies (PCSK9-mAb) have been studied intensively to identify their effect in lowering levels of low density lipoprotein cholesterol (LDL-C). However, the applicable target of PCSK9-mAbs remains inconclusive so far. Therefore, this first...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Jun Qian, Yao Gao, Yan Mei Zhang, Ming Chu, Jing Yao, Di Xu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/47c8bd2e03c642a8be6106b380aac82d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:47c8bd2e03c642a8be6106b380aac82d
record_format	dspace
spelling	oai:doaj.org-article:47c8bd2e03c642a8be6106b380aac82d2021-12-02T12:30:27ZTherapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials10.1038/s41598-017-00316-32045-2322https://doaj.org/article/47c8bd2e03c642a8be6106b380aac82d2017-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00316-3https://doaj.org/toc/2045-2322Abstract Proprotein convertase subtilisin/kexin9 monoclonal antibodies (PCSK9-mAb) have been studied intensively to identify their effect in lowering levels of low density lipoprotein cholesterol (LDL-C). However, the applicable target of PCSK9-mAbs remains inconclusive so far. Therefore, this first meta-analysis was carried out to clarify the therapeutic efficacy and safety of PCSK9-mAbs on the potential patients: familial hypercholesterolemia and statin-intolerant patients. All randomized controlled trials that met the search terms were retrieved in multiple databases. Efficacy outcomes included parameter changes from baseline in LDL-C and other lipid levels. Therapeutic safety were evaluated by rates of common adverse events. A total of 15 studies encompassing 4,288 patients with at least 8 weeks duration were selected. Overall, the therapeutic efficacy was achieved with significant reduction in LDL-C, TC, TG, Lp(a), Apo-B versus placebo. The decline in familial hypercholesterolemia patients (−53.28%, 95% CI: −59.88 to −46.68%) was even more obvious than that in statin-intolerant patients (−34.95%, 95% CI: −41.46 to −28.45%). No obvious safety difference was found out in the rates of common and serious adverse events. To conclude, PCSK9-mAb contributes to the decreased level of LDL-C and other lipids in familial hypercholesterolemia and statin-intolerant patients with satisfactory safety and tolerability.Li Jun QianYao GaoYan Mei ZhangMing ChuJing YaoDi XuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Li Jun Qian Yao Gao Yan Mei Zhang Ming Chu Jing Yao Di Xu Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
description	Abstract Proprotein convertase subtilisin/kexin9 monoclonal antibodies (PCSK9-mAb) have been studied intensively to identify their effect in lowering levels of low density lipoprotein cholesterol (LDL-C). However, the applicable target of PCSK9-mAbs remains inconclusive so far. Therefore, this first meta-analysis was carried out to clarify the therapeutic efficacy and safety of PCSK9-mAbs on the potential patients: familial hypercholesterolemia and statin-intolerant patients. All randomized controlled trials that met the search terms were retrieved in multiple databases. Efficacy outcomes included parameter changes from baseline in LDL-C and other lipid levels. Therapeutic safety were evaluated by rates of common adverse events. A total of 15 studies encompassing 4,288 patients with at least 8 weeks duration were selected. Overall, the therapeutic efficacy was achieved with significant reduction in LDL-C, TC, TG, Lp(a), Apo-B versus placebo. The decline in familial hypercholesterolemia patients (−53.28%, 95% CI: −59.88 to −46.68%) was even more obvious than that in statin-intolerant patients (−34.95%, 95% CI: −41.46 to −28.45%). No obvious safety difference was found out in the rates of common and serious adverse events. To conclude, PCSK9-mAb contributes to the decreased level of LDL-C and other lipids in familial hypercholesterolemia and statin-intolerant patients with satisfactory safety and tolerability.
format	article
author	Li Jun Qian Yao Gao Yan Mei Zhang Ming Chu Jing Yao Di Xu
author_facet	Li Jun Qian Yao Gao Yan Mei Zhang Ming Chu Jing Yao Di Xu
author_sort	Li Jun Qian
title	Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
title_short	Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
title_full	Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
title_fullStr	Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
title_full_unstemmed	Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
title_sort	therapeutic efficacy and safety of pcsk9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: a meta-analysis of 15 randomized controlled trials
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/47c8bd2e03c642a8be6106b380aac82d
work_keys_str_mv	AT lijunqian therapeuticefficacyandsafetyofpcsk9monoclonalantibodiesonfamilialhypercholesterolemiaandstatinintolerantpatientsametaanalysisof15randomizedcontrolledtrials AT yaogao therapeuticefficacyandsafetyofpcsk9monoclonalantibodiesonfamilialhypercholesterolemiaandstatinintolerantpatientsametaanalysisof15randomizedcontrolledtrials AT yanmeizhang therapeuticefficacyandsafetyofpcsk9monoclonalantibodiesonfamilialhypercholesterolemiaandstatinintolerantpatientsametaanalysisof15randomizedcontrolledtrials AT mingchu therapeuticefficacyandsafetyofpcsk9monoclonalantibodiesonfamilialhypercholesterolemiaandstatinintolerantpatientsametaanalysisof15randomizedcontrolledtrials AT jingyao therapeuticefficacyandsafetyofpcsk9monoclonalantibodiesonfamilialhypercholesterolemiaandstatinintolerantpatientsametaanalysisof15randomizedcontrolledtrials AT dixu therapeuticefficacyandsafetyofpcsk9monoclonalantibodiesonfamilialhypercholesterolemiaandstatinintolerantpatientsametaanalysisof15randomizedcontrolledtrials
_version_	1718394330597556224

Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials

Ejemplares similares